Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

July 31, 2025

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to...

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Sage Therapeutics Announces Second Quarter 2025 Financial Results

July 30, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

July 28, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

July 25, 2025

From Biogen Inc.

Via GlobeNewswire

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders

July 05, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

July 01, 2025

From FN Media Group LLC

Via GlobeNewswire

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

July 01, 2025

EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

June 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders

June 25, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders

June 17, 2025

From Halper Sadeh LLC

Via GlobeNewswire

June 17, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

June 16, 2025

From Halper Sadeh LLC

Via Business Wire

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

June 16, 2025

From Ademi & Fruchter LLP

Via Business Wire

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

June 16, 2025

From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.

Via GlobeNewswire

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

April 29, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

April 15, 2025

From Sage Therapeutics, Inc.

Via Business Wire

SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE

April 11, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

March 17, 2025

From Grabar Law Office

Via GlobeNewswire

SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE

March 17, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your

March 14, 2025

From Grabar Law Office

Via GlobeNewswire

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

March 13, 2025

From Grabar Law Office

Via GlobeNewswire

Long-Term Shareholder Notice: Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

March 12, 2025

From Grabar Law Office

Via GlobeNewswire

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf as

March 10, 2025

From Grabar Law Office

Via GlobeNewswire

Sage Therapeutics Announces R&D Leadership Transition

March 04, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

February 11, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

January 28, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal

January 27, 2025

From Sage Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.